For many families affected by neuroendocrine cancer, supporting research becomes a deeply personal mission. For Wayne Firsty and his children, Shay and Alana, that commitment
Clinical Trials Highlight Advances in Neuroendocrine Tumor Research Research into neuroendocrine tumors (NETs) continues to progress, with clinical trials exploring both new treatment approaches and
More than one thousand neuroendocrine cancer researchers, physicians, and patient advocates from over 50 countries gathered this month in Krakow, Poland, for the 23rd Annual
By Anna C. Greene, PhD, NETRF Chief Scientific Officer In recent years, you may have seen headlines and commentaries suggesting that neuroendocrine cancers are “no
By Anna C. Greene, PhD, NETRF Chief Scientific Officer A new open-access review article in Virchows Archiv, “Novel concepts of cell-of-origin in neuroendocrine neoplasms,” by
Jamie Metzl is a writer and technology/health care futurist who regularly speaks to the medical industry on the future of health care. When Jamie’s father,
The Neuroendocrine Tumor Research Foundation (NETRF) today announced its latest round of neuroendocrine cancer research grant recipients. The thirteen investigators receiving awards are pursuing innovative,
In November 2025, Drew Greenberg marked his Bar Mitzvah in a way that moved everyone who heard his story. At just 13 years old, Drew
By Anna C. Greene, PhD, NETRF Chief Scientific Officer At the Neuroendocrine Tumor Research Foundation (NETRF), we often hear a familiar story: symptoms that don’t
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat